Publications

2025

Cannabinoid 1 receptor availability in posttraumatic stress disorder: A positron emission tomography study
Korem N, Bassir Nia A, Hillmer A, D’Souza D, Nabulsi N, Huang Y, Cosgrove K, Levy I, Pietrzak R, Harpaz-Rotem I. Cannabinoid 1 receptor availability in posttraumatic stress disorder: A positron emission tomography study. Translational Psychiatry 2025, 15: 310. PMID: 40846835, PMCID: PMC12373994, DOI: 10.1038/s41398-025-03519-9.
Peer-Reviewed Original Research
The Potential Use of Cannabidiol in the Treatment of Opioid Use Disorder: A Systematic Review
Shafie M, Ing K, Rostam‐Abadi Y, Weleff J, Griffin M, Ranganathan M, Aghaei A, Pratt N, Funaro M, Nia A. The Potential Use of Cannabidiol in the Treatment of Opioid Use Disorder: A Systematic Review. Addiction Biology 2025, 30: e70047. PMID: 40415392, PMCID: PMC12104536, DOI: 10.1111/adb.70047.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
MeSH Keywords
The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies
Weleff J, Pulido-Saavedra A, Aghaei A, Ing K, Arakelian M, Fontanele R, Nero N, Barnett B, Anand A, Nia A, Angarita G. The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies. Psychiatry Research 2025, 348: 116446. PMID: 40147088, PMCID: PMC12306858, DOI: 10.1016/j.psychres.2025.116446.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
The Contribution of Psychotherapy in Potential Therapeutic Effects of Psychedelics for Treatment of Opioid Use Disorder
Bassir Nia A, Farahmand Y, Griffith G, Ardavan M, Angarita G, Anand A, Pittenger C. The Contribution of Psychotherapy in Potential Therapeutic Effects of Psychedelics for Treatment of Opioid Use Disorder. Current Addiction Reports 2025, 12: 20. PMID: 42368319, PMCID: PMC13308683, DOI: 10.1007/s40429-025-00638-7.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies
Pulido-Saavedra A, Oliva H, Prudente T, Kitaneh R, Nunes E, Fogg C, Funaro M, Weleff J, Nia A, Angarita G. Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies. Cellular And Molecular Life Sciences 2025, 82: 49. PMID: 39833376, PMCID: PMC11747050, DOI: 10.1007/s00018-024-05519-2.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
MeSH Keywords

2024

Endocannabinoid Signaling and Food Addiction
Bassir Nia A, D’souza D. Endocannabinoid Signaling and Food Addiction. 2024, 146-156. DOI: 10.1093/oso/9780190671051.003.0017.
Peer-Reviewed Original Research
Amygdala Cannabinoid 1 Receptor, Pain Response, and Emotional Numbing in Trauma-Exposed Individuals
Korem N, Hillmer A, D’Souza D, Nia A, Levy I, Pietrzak R, Harpaz-Rotem I. Amygdala Cannabinoid 1 Receptor, Pain Response, and Emotional Numbing in Trauma-Exposed Individuals. JAMA Network Open 2024, 7: e2432387. PMID: 39250156, PMCID: PMC11385051, DOI: 10.1001/jamanetworkopen.2024.32387.
Peer-Reviewed Original Research
MeSH Keywords
Sex differences in the acute effects of oral THC: a randomized, placebo-controlled, crossover human laboratory study
Mohammad Aghaei A, Urban Spillane L, Pittman B, Flynn L, De Aquino J, Bassir Nia A, Ranganathan M. Sex differences in the acute effects of oral THC: a randomized, placebo-controlled, crossover human laboratory study. Psychopharmacology 2024, 241: 2145-2155. PMID: 38832949, PMCID: PMC12954630, DOI: 10.1007/s00213-024-06625-6.
Peer-Reviewed Original Research
Psychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder
Mohammad Aghaei A, Weleff J, Martins B, Ing K, Fontenele R, Barnett B, Anand A, Bassir Nia A. Psychotherapeutic Interventions in Clinical Trials of Psychedelics for the Treatment of Alcohol Use Disorder. Current Addiction Reports 2024, 11: 685-712. DOI: 10.1007/s40429-024-00574-y.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

2023

Dysregulation of the endogenous cannabinoid system following opioid exposure
Aghaei A, Saali A, Canas M, Weleff J, D’Souza D, Angarita G, Nia A. Dysregulation of the endogenous cannabinoid system following opioid exposure. Psychiatry Research 2023, 330: 115586. PMID: 37931479, PMCID: PMC10842415, DOI: 10.1016/j.psychres.2023.115586.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
MeSH Keywords
Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges
Barnett B, Nia A, Sackett N, Weleff J. Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges. Frontiers In Psychiatry 2023, 14: 1305478. PMID: 37928914, PMCID: PMC10622752, DOI: 10.3389/fpsyt.2023.1305478.
Commentaries, Editorials and Letters
Regular cannabis use is associated with history of childhood and lifetime trauma in a non-clinical community sample
Nia A, Weleff J, Fogelman N, Nourbakksh S, Sinha R. Regular cannabis use is associated with history of childhood and lifetime trauma in a non-clinical community sample. Journal Of Psychiatric Research 2023, 159: 159-164. PMID: 36736285, PMCID: PMC10024801, DOI: 10.1016/j.jpsychires.2023.01.036.
Peer-Reviewed Original Research
MeSH Keywords
Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis
Nia A, Spriggs S, Jankowski S, DeFrancisco D, Swift A, Perkel C, Galynker I, Honrao C, Makriyannis A, Hurd Y. Cannabis use is associated with low plasma endocannabinoid Anandamide in individuals with psychosis. Journal Of Psychopharmacology 2023, 37: 484-489. PMID: 36633290, DOI: 10.1177/02698811221148604.
Peer-Reviewed Original Research
MeSH Keywords

2022

Illness Phase as a Key Assessment and Intervention Window for Psychosis
Kohler C, Wolf D, Abi-Dargham A, Cho Y, Fonteneau C, Girgis R, Gray D, Grinband J, Javitch J, Kantrowitz J, Krystal J, Lieberman J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Group T, D'Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gur R, Gur R, Calkins M. Illness Phase as a Key Assessment and Intervention Window for Psychosis. Biological Psychiatry Global Open Science 2022, 3: 340-350. PMID: 37519466, PMCID: PMC10382701, DOI: 10.1016/j.bpsgos.2022.05.009.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC)
Bassir Nia A, Orejarena MJ, Flynn L, D’Souza D, Pittman B, Ranganathan M. Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC). Psychopharmacology 2022, 239: 1621-1628. PMID: 35438304, PMCID: PMC11215802, DOI: 10.1007/s00213-022-06135-3.
Peer-Reviewed Original Research
MeSH Keywords

2021

Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
Abi-Dargham A, Javitch JA, Slifstein M, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, D’Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin 2021, 48: 199-210. PMID: 34423843, PMCID: PMC8781338, DOI: 10.1093/schbul/sbab095.
Peer-Reviewed Original Research
MeSH Keywords

2020

Multimodal Computational Modeling of Visual Object Recognition Deficits but Intact Repetition Priming in Schizophrenia
Sehatpour P, Nia A, Adair D, Wang Z, DeBaun H, Silipo G, Martinez A, Javitt D. Multimodal Computational Modeling of Visual Object Recognition Deficits but Intact Repetition Priming in Schizophrenia. Frontiers In Psychiatry 2020, 11: 547189. PMID: 33329086, PMCID: PMC7719812, DOI: 10.3389/fpsyt.2020.547189.
Peer-Reviewed Original Research
Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity
Nia A, Spriggs SA, DeFrancisco D, Swift A, Perkel C, Zhong X, Mazumdar M, Fernandez N, Patel M, Kim-Schulze S, Hurd YL. Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity. Psychiatry Research 2020, 293: 113380. PMID: 32818918, PMCID: PMC8292796, DOI: 10.1016/j.psychres.2020.113380.
Peer-Reviewed Original Research
MeSH Keywords

2019

The Relevacen of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population
Bassir Nia A, Mann CL, Spriggs S, DeFrancisco DR, Carbonaro S, Parvez L, Galynker II, Perkel CA, Hurd YL. The Relevacen of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population. The Journal Of Clinical Psychiatry 2019, 80: 18m12539. PMID: 31265768, PMCID: PMC8445109, DOI: 10.4088/jcp.18m12539.
Peer-Reviewed Original Research
MeSH Keywords
Endocannabinoid System Alterations in Posttraumatic Stress Disorder: A Review of Developmental and Accumulative Effects of Trauma
Nia A, Bender R, Harpaz-Rotem I. Endocannabinoid System Alterations in Posttraumatic Stress Disorder: A Review of Developmental and Accumulative Effects of Trauma. Chronic Stress 2019, 3: 2470547019864096. PMID: 31660473, PMCID: PMC6816276, DOI: 10.1177/2470547019864096.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

2018

The Neurobiology of Borderline Personality Disorder
Perez-Rodriguez M, Bulbena-Cabré A, Nia A, Zipursky G, Goodman M, New A. The Neurobiology of Borderline Personality Disorder. Psychiatric Clinics Of North America 2018, 41: 633-650. PMID: 30447729, DOI: 10.1016/j.psc.2018.07.012.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
MeSH Keywords
Cannabis Use: Neurobiological, Behavioral, and Sex/Gender Considerations
Bassir Nia A, Mann C, Kaur H, Ranganathan M. Cannabis Use: Neurobiological, Behavioral, and Sex/Gender Considerations. Current Behavioral Neuroscience Reports 2018, 5: 271-280. PMID: 31548918, PMCID: PMC6756752, DOI: 10.1007/s40473-018-0167-4.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
Current Knowledge on Gene-Environment Interactions in Personality Disorders: an Update
Bulbena-Cabre A, Bassir Nia A, Perez-Rodriguez MM. Current Knowledge on Gene-Environment Interactions in Personality Disorders: an Update. Current Psychiatry Reports 2018, 20: 74. PMID: 30094700, DOI: 10.1007/s11920-018-0934-7.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
MeSH Keywords
Cannabidiol, an Adjunct Player in the Antipsychosis Arsenal
Bassir Nia A, Hurd YL. Cannabidiol, an Adjunct Player in the Antipsychosis Arsenal. American Journal Of Psychiatry 2018, 175: 197-198. PMID: 29490489, DOI: 10.1176/appi.ajp.2017.17121295.
Commentaries, Editorials and Letters
MeSH Keywords

2017

Opioid addiction and borderline personality disorder
Bassir Nia A. Opioid addiction and borderline personality disorder. American Journal On Addictions 2017, 27: 54-55. PMID: 29283477, DOI: 10.1111/ajad.12664.
Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

See All Publications